Three global pharmaceutical companies and the technology transfer offices of three world-leading universities – Imperial College London, University College London and the University of Cambridge – have joined forces with a combined £40 million to create the Apollo Therapeutics Fund.
An innovative new Consortium will act as a ‘match-making’ service between pharmaceutical companies and researchers in Cambridge with the aim of developing and studying precision medicines for some of the most globally devastating diseases.
Alzheimer’s Research UK, the world’s largest dedicated dementia research charity, has announced a £30 million Drug Discovery Alliance, launching three flagship Drug Discovery Institutes at the Universities of Cambridge, Oxford and UCL (University College London). The Drug Discovery Institutes will see 90 new research scientists employed in state-of-the-art facilities to fast-track the development of new treatments for Alzheimer’s disease and other dementias.
Eve, an artificially-intelligent ‘robot scientist’ could make drug discovery faster and much cheaper, say researchers writing in the Royal Society journal Interface. The team has demonstrated the success of the approach as Eve discovered that a compound shown to have anti-cancer properties might also be used in the fight against malaria.
New study describes a fundamental mechanism regulating a protein’s shape and function, with potential applications in biotechnology and drug development.
A combination of nanotechnology and a unique twisting property of light could lead to new methods for ensuring the purity and safety of pharmaceuticals.
Cambridge researchers developing new therapies as part of a collaborative programme with industry.
Can better decisions be made about which anticancer drugs to progress to clinical trials?
GlaxoSmithKline (GSK) has signed its first agreement with the University to optimise the early clinical development of new GSK medicines for obesity and addictive disorders.
© 2025 University of Cambridge